NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on September 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on September 29, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 25 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X700. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 1,013,515. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the reverse stock split, CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
TEL AVIV, ISRAEL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Arbe Robotics Ltd. (NASDAQ: ARBE), (TASE: ARBE) (“Arbe” or the “Company”), a global leader in ultra-high-resolution radar solutions, today announced that it has priced an underwritten registered direct offering of 833,334 ordinary shares at a purchase price of $0.60 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 24,166,666 ordinary shares at a purchase price of $0.5999 per share, which equals the offering price per ordinary share less the $0.0001 exercise price per share of each pre-funded warrant. The pre-funded warrants are immediately exercisable and will not expire until exercised in full. All ordinary shares and pre-funded warrants to be sold in the offering will be offered by the Company.
Arbe estimates the gross proceeds from this offering to be approximately $15 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 28, 2026, subject to the satisfaction of customary closing conditions. Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes, including, but not limited to, scaling its operations to support growing commercial opportunities, including the recently announced selection of Arbe’s radar technology for an L3 passenger vehicle program of one of the world’s largest automotive groups and its intended expansion into the defense and counter-drone markets, as well as to potentially pursue potential strategic merger and acquisition opportunities.
Canaccord Genuity is acting as sole bookrunner for the offering.
The securities described above are being offered pursuant to a registration statement on Form F-3 (File No. 333-287805), originally filed on June 5, 2025, with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on June 13, 2025. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor, Boston, MA 02109, or by email at prospectus@cgf.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Arbe Robotics Ltd.
Arbe (NASDAQ: ARBE), a global leader in ultra-high-resolution radar solutions, is redefining radar as a core sensing platform for next-generation mobility and defense. Arbe’s complete radar technology stack, from proprietary chipsets to radar systems and AI algorithms that produce perception-ready data, delivers the detail and real-time processing that demanding sensing applications require. Arbe enables OEMs, Tier-1s, and defense integrators to build more capable perception systems for passenger vehicles, robotaxis, heavy machinery, and counter-drone systems. Headquartered in Tel Aviv, Israel, Arbe also operates offices in the United States, Germany, and China. For more information, visit https://arberobotics.com/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended by the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the expected timing, completion or size of the offering, the expected gross proceeds therefrom, and the intended use of net proceeds therefrom. The words “expect,” “believe,” “estimate,” “intend,” “plan,” “anticipate,” “may,” “should,” “strategy,” “future,” “will,” “project,” “potential” and similar expressions indicate forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These risks and uncertainties include the possible delisting of the Company’s ordinary shares from Nasdaq in the event the bid price per share of the Company’s ordinary shares remains below $1.00, the effect on the Israeli economy generally and on the Company’s business resulting from the terrorism and the hostilities in Israel, including the continuing hostilities with Iran, Hezbollah and Hamas and any intensification of hostilities, and the effect of the call-up of a significant portion of its working population, including the Company’s employees, the ability of the Company to develop and market the Alerion radar system and deliver units in a timely and profitable manner, the ability of the Alerion radar system to operate as planned under wartime conditions, and the risks and uncertainties described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” and in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026, as well as other documents filed by the Company with the SEC. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.
In accordance with section 30 of the Capital Markets Act, Tryg A/S (“Tryg”) hereby announces that BlackRock, Inc. has notified Tryg that BlackRock, Inc. holds shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets Act, corresponding to more than 5% of the entire share capital and voting rights of Tryg. Please see further details in the attached notification form.
Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).
Long considered an incurable disease, multiple myeloma is entering a new phase in which some patients are remaining free of detectable disease for years after treatment ends. Significant advances in both myeloma therapeutic strategies and disease monitoring technologies are giving clinicians more effective ways to drive deep responses and more sensitive ways to measure them. As more patients achieve these outcomes, a clear standard for determining when a long-term response may be considered a cure is necessary. The new consensus definition establishes that standard and places sustained measurable residual disease (MRD) negativity at the center of determining whether a deep response has endured over time.
Under the consensus definition reached by global myeloma experts, a patient with newly diagnosed or relapsed disease may be considered cured after five years in complete remission without any myeloma treatment. During that period, the definition requires:
At least four negative MRD assessments, including one at the five-year mark, with no positive result in between.
MRD tests must use next-generation sequencing or next-generation flow at a sensitivity of 10⁻⁶, or one myeloma cell among one million cells.
Advanced imaging, using PET/CT or diffusion-weighted whole-body MRI, must show no disease at the start and end of the period, with no positive scan in between if additional scans are performed.
These criteria illustrate that advanced disease assessment methodologies, including clonoSEQ®, will play a central role in determining which patients meet the definition of cure.
“In the world of treating multiple myeloma, we have now reached a point where we can actually cure patients. Part of that cure definition is that the patient has no measurable disease in their bone marrow,” said Dr. Jeffrey Wolf, clinical professor, Department of Medicine, University of California, San Francisco. “The ideal way of measuring that is to use the clonoSEQ Assay, which has been proven over many years to be the most reproducible way of defining residual disease in these patients.”
Establishing this consensus definition is the beginning of a new era for patients; significant ongoing research will be required to continue to expand the fraction who are cured and to better understand the probability of cure in specific patient subpopulations.
“Patients are excited to hear the cure conversation gain momentum but want to balance the hope with their lived reality,” said Jenny Ahlstrom, myeloma patient and CEO and founder, HealthTree Foundation. “Given that all myeloma is not the same, learning who can and will be cured will be one of the most important discoveries in the near future.”
“The consensus definition of cure in myeloma marks a defining moment for the patient community and a landmark achievement for the field. Together with last week’s NCCN Guidelines® update, this development clearly affirms that highly sensitive MRD assessment should be systematically integrated into routine myeloma care,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “As the first and only FDA-cleared next-generation sequencing MRD test, clonoSEQ is uniquely positioned to support the level of rigor the cure definition requires, giving clinicians a precise way to measure deep responses over time and offering patients clearer insight into the outcome of their treatment.”
About clonoSEQ clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ has been extensively studied in more than 300 peer-reviewed publications.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.
To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
HERNDON, Va., Sept. 25, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) has appointed Diane Offereins, a well-respected executive with over 35 years of experience in financial services, to the Navient board of directors, effective September 24, 2026.
“We are excited to have Diane join the Navient board and believe she is an excellent addition with her many years of experience in the financial services industry and expertise in executive compensation, information technology and cybersecurity,” said Edward Bramson, CEO and chair of the Navient board of directors.
Offereins is currently serving on the boards of Lendbuzz, Flywire and Brighthouse Financial following over 24 years with Discover Financial Services where she served as Global Chief Information Officer and completing her career as Executive Vice President, Payment Services. She graduated with a BBA in accounting from Loyola University in New Orleans.
This appointment comes after the retirement of a board member in June 2026.
About Navient Navient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business, we help customers confidently achieve financial success through digital financial services. Our employees thrive in a culture of belonging, where they are supported and proud to deliver meaningful outcomes. Learn more on Navient.com.
ORLANDO, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the appointment of Robert J. O’Neill to its Advisory Board. O’Neill is a highly decorated former U.S. Navy SEAL, New York Times best-selling author, and nationally recognized speaker on leadership and resilience.
O’Neill served 16 years in the U.S. Navy, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), and took part in more than 400 combat missions across four theaters of war. He is widely known for his role in Operation Neptune’s Spear, the 2011 mission that resulted in the death of Osama bin Laden. Over his career he was decorated more than 50 times, including two Silver Stars and four Bronze Stars with Valor. He is the author of the New York Times best-selling memoir The Operator: Firing the Shots That Killed Osama bin Laden and My Years as a SEAL Team Warrior, and is a regular contributor to national media on leadership, decision-making under pressure, and national security.
O’Neill remains closely connected to the military and veteran community, and has been a visible advocate for expanding access to emerging health treatments, including appearing alongside fellow veterans at this year’s White House executive order signing aimed at accelerating research and access to psychedelic-assisted therapies through the VA. His continued engagement with veteran service organizations and the broader military community reflects a career-long commitment to those he served alongside. His experience in fighting for adequate care pairs perfectly with Nutriband’s advancement of AVERSA as the company continues towards approval and commercialization of AVERSA Fentanyl which would be the worlds first and only abuse deterrent fentanyl patch if approved.
“Rob has spent his career operating at the highest levels of pressure, precision, and decision-making, and he’s continued that same commitment through his advocacy for adequate care and the military community he comes from,” said Gareth Sheridan, CEO of Nutriband Inc. “Those are exactly the qualities we look for as we scale Nutriband and AVERSA™ into new markets, and his perspective will be a real asset to our team as we continue to grow.”
Nutriband’s Advisory Board supports the Company’s executive team on strategy, growth, and execution as it advances its pipeline of abuse-deterrent transdermal products, including AVERSA™ Fentanyl.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information: Nutriband Inc. Phone: 407-377-6695 Email: info@nutriband.com
Bullard Ave & McDowell Rd Location to Celebrate Grand Opening on September 27th
Black Rock Coffee Bar
Opening September 27 in Goodyear
Black Rock Coffee Bar
New Goodyear Location – Opening September 27
Scottsdale, AZ, Sept. 25, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, the Oregon-born boutique coffee company known for its specialty coffees, teas, smoothies, and popular Fuel® energy drinks, is expanding its footprint in the Valley with a new location opening this week.
The store, located at 14880 W McDowell Rd will officially celebrate its grand opening in Goodyear on Sunday, September 27th. Guests can enjoy $3 medium drinks all day, with the celebration continuing into the following day with a signature grand opening sticker giveaway. With this opening, Black Rock’s Arizona presence grows to 63 locations, underscoring the brand’s steady expansion throughout the Valley.
“As we continue to grow throughout the Valley, we’re excited to open another location in Goodyear,” said Mark Davis, CEO of Black Rock Coffee Bar. “We’re looking forward to introducing more guests to the Black Rock experience and creating a welcoming place to fuel their day.”
Guests can also take advantage of the Black Rock Rewards app, where every purchase—whether in-store, online, or through the app—earns “bolts” that can be redeemed for free beverages. Recent menu additions, like Black Rock’s protein-packed Egg Bites, are also included in the program.
Black Rock Coffee Bar is beloved for its handcrafted beverages, including the Caramel Blondie, a sweet and creamy signature blend; the Mexican Mocha, a spicy twist with hints of vanilla, almond, and cinnamon; and the Jackhammer, a vanilla mocha with an extra double shot; as well as its in-house developed Fuel energy drink, customizable with over 20 fruit flavors. These can be enjoyed alongside sweet and savory food items, including the recently launched Grilled Cheese and Pumpkin Blondie Cake Pop. For an extra kick of protein, guests can add Black Rock’s new Protein Cold Foam, Protein Boosted Milk or Protein Boost to their drinks.
In addition to Black Rock menu staples, guests can enjoy limited-time offerings like the Pumpkin Spiced Latte, Pumpkin Blondie, and Pumpkin Spice Cookie Latte with Cookie Butter Cold Foam. The brand’s Fall Remix seasonal drinks are also now available, featuring the Caramel Apple Butter Shaken Espresso, Cinnamon Bun Latte, and Spellbound Berry Fuel, offering a mix of nostalgic and refreshing flavors.
For more information, visit https://br.coffee/ and follow @blackrockcoffeebar on Facebook and Instagram, and @blackrockcoffeeofficial on TikTok for updates on new locations, promotions, and seasonal offerings.
About Black Rock Coffee Bar
Black Rock Coffee Bar is a national boutique coffee shop that is known for its premium roasted coffees, teas, smoothies and flavorful Fuel® energy drinks. Founded as a family owned and operated business in Oregon in 2008, Black Rock Coffee Bar has grown to over 200 retail locations in seven states. The Black Rock culture prides itself on not only being a positive force for the communities it serves, but also the team members that fuel their locations day in and day out. An important aspect of their team mission is to recognize those that go above and beyond by displaying the 4G’s of Black Rock – grit, growth, gratitude, and grace. For more information, visit https://br.coffee/.
New York, NY, Sept. 25, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (Nasdaq: ALP) (“Alpha Compute” or the “Company”), a provider of high-density AI compute infrastructure and enterprise GPU services, today announced that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
On March 2, 2026, Nasdaq’s Listing Qualifications Staff (the “Staff”) notified the Company that its Ordinary Shares had failed to maintain a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
The Company is pleased to announce that the Staff has determined that, for the 11 consecutive business days from September 9, 2026 through September 23, 2026, the closing bid price of the Company’s Ordinary Shares was at or above $1.00 per share.
Accordingly, Alpha Compute has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
“We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement,” said Wes Levitt, Chief Financial Officer of Alpha Compute. “This milestone reflects our continued focus on strengthening the Company and delivering long-term value for our shareholders.”
About Alpha Compute Corp.
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute. Alpha Compute’s mission is to support clients, subsidiaries, and partners across critical sectors including: finance, defense, intelligence, and media with the essential framework for any organization requiring secure, confidential computing environments. For more information, please visit: https://www.alphacompute.ai/
Alpha Compute Corp. is domiciled in the British Virgin Islands and Delaware with offices in New York, Los Angeles, Miami, Amsterdam and Toronto, and is a founding partner of the Right2Compute Coalition (www.right2compute.com).
Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements.
Forward-looking statements in this release include, without limitation: successful completion of the Tioga East acquisition and the development and financing of the planned data center, the; title, acreage and net revenue interest; financing and partner arrangements; gas availability, projected power costs, well and generation plans; development, permitting, construction and commercial operation of the planned initial 200 MW; potential expansion to 1 GW; and potential economic, environmental and community impacts.
These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the timing and progress of the Company’s strategic initiatives; reliance on third-party vendors and partners; the ability to secure additional financing; uncertainty around the Company’s investments and legacy business; risks related to technology platforms and ecosystems; and general market and economic conditions. A more complete discussion of these risks is set forth under “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2026.
Undue reliance should not be placed on these forward-looking statements. The forward-looking statements contained herein are made as of the date of this press release, and the Company undertakes no obligation to update or revise them publicly, except as required by law.
Scottsdale, AZ, Sept. 25, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, the Oregon-born boutique coffee chain celebrated for its specialty coffees, teas, smoothies, and signature Fuel® energy drinks, is growing its footprint in California with the opening of a new store in Montclair.
The store, located at 8970 Central Ave, will officially open its doors on Wednesday, September 30th. This opening marks Black Rock’s seventh California location and reinforces the brand’s steady expansion across the state. Guests can enjoy the following specials during opening week:
Wednesday, 9/30: Free 16oz Drinks
Thursday, 10/1: Buy One, Get One Free Drinks
Friday, 10/2: 50% Off a Drink w/ Food Purchase
Saturday, 10/3: Signature Grand Opening Sticker with purchase while supplies last
Sunday, 10/4: Free T-Shirt with purchase while supplies last
Monday, 10/5: $2 Off Any Size Drink
“California has been an important part of Black Rock’s growth, and we’re excited to expand into Montclair,” said Mark Davis, CEO of Black Rock Coffee Bar. “We look forward to becoming part of the community and creating a welcoming place for guests to enjoy their favorite drinks and fuel their day!”
Guests can also take advantage of the Black Rock Rewards app, where every purchase—whether in-store, online, or through the app—earns “bolts” that can be redeemed for free beverages. Recent menu additions, like Black Rock’s protein-packed Egg Bites, are also included in the program.
Black Rock Coffee Bar is beloved for its handcrafted beverages, including the Caramel Blondie, a sweet and creamy signature blend; the Mexican Mocha, a spicy twist with hints of vanilla, almond, and cinnamon; and the Jackhammer, a vanilla mocha with an extra double shot; as well as its in-house developed Fuel energy drink, customizable with over 20 fruit flavors. These can be enjoyed alongside sweet and savory food items, including the recently launched Grilled Cheese and Pumpkin Blondie Cake Pop. For an extra kick of protein, guests can add Black Rock’s new Protein Cold Foam, Protein Boosted Milk or Protein Boost to their drinks.
In addition to Black Rock menu staples, guests can enjoy limited-time offerings like the Pumpkin Spiced Latte, Pumpkin Blondie, and Pumpkin Spice Cookie Latte with Cookie Butter Cold Foam. The brand’s Fall Remix seasonal drinks are also now available, featuring the Caramel Apple Butter Shaken Espresso, Cinnamon Bun Latte, and Spellbound Berry Fuel, offering a mix of nostalgic and refreshing flavors.
For more information, visit https://br.coffee/ and follow @blackrockcoffeebar on Facebook and Instagram, and @blackrockcoffeeofficial on TikTok for updates on new locations, promotions, and seasonal offerings.
About Black Rock Coffee Bar
Black Rock Coffee Bar is a national boutique coffee shop that is known for its premium roasted coffees, teas, smoothies and flavorful Fuel® energy drinks. Founded as a family owned and operated business in Oregon in 2008, Black Rock Coffee Bar has grown to over 200 retail locations in seven states. The Black Rock culture prides itself on not only being a positive force for the communities it serves, but also the team members that fuel their locations day in and day out. An important aspect of their team mission is to recognize those that go above and beyond by displaying the 4G’s of Black Rock – grit, growth, gratitude, and grace. For more information, visit https://br.coffee/.
NANO Nuclear, IP3 and Cybernetic Intelligence Sign Letter of Intent to Pursue Nuclear Powered AI Infrastructure Projects
Letter of Intent Names NANO Nuclear as a Preferred Nuclear Technology & Services Provider for Potential Future Projects
New York, N.Y., Sept. 25, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or the “Company”), IP3 Corporation (“IP3”) and Cybernetic Intelligence announced the signing a Letter of Intent (LOI) setting out a framework to jointly pursue nuclear-powered artificial intelligence (AI), national security and computing and other infrastructure opportunities in the United States and select international markets.
The LOI names NANO Nuclear as a preferred provider of nuclear technology and services to IP3 and Cybernetic Intelligence for opportunities pursued through the collaboration. The relationship is expected to leverage NANO Nuclear’s capabilities across advanced microreactor technology, nuclear fuel supply and logistics, and reactor operations.
Figure 1 – NANO Nuclear, IP3 and Cybernetic Intelligence Sign Letter of Intent to Pursue Nuclear Powered AI Infrastructure Projects
Enabling Potential New Commercial Pathways for Advanced Nuclear
NANO Nuclear believes growing demand for secure, reliable and resilient power across AI, national security and computing and other critical infrastructure will create new applications for advanced nuclear technology beyond traditional utility-scale generation.
The collaboration brings together complementary capabilities intended to help convert those opportunities into potential commercial projects: NANO Nuclear as a provider of advanced nuclear technology, fuel and related services; IP3 providing project origination, development, financing and government engagement capabilities; and Cybernetic Intelligence contributing expertise in AI infrastructure, compute sovereignty and access to potential defense, intelligence and commercial compute customers.
Together, the parties intend to pursue an integrated development approach that connects advanced nuclear technology with identifiable energy demand, secure computing requirements, project development and potential access to capital. This is expected to include identifying potential end-users and host sites, assessing applicable regulatory and policy frameworks, developing project and feasibility materials, engaging potential financing and project partners, and evaluating the supply-chain and manufacturing capabilities required to support deployment.
The parties also expect to evaluate potential financing pathways for mutually agreed projects, including infrastructure and project finance, government-supported programs and other sources of institutional capital. These activities are intended to create a potential pathway from opportunity origination and project structuring through financing and commercial deployment.
Pursuing a Pipeline of Strategic Commercial Opportunities
The parties intend to jointly evaluate and pursue multiple potential commercial opportunities across the United States and select international markets. Areas under consideration include potential advanced reactor pilot programs for military applications, energy-resilience solutions for defense and intelligence installations, sovereign AI and high-performance computing infrastructure, maritime nuclear applications, and strategic international energy and infrastructure projects.
As an initial workstream under the LOI, the parties intend to identify and commence a mutually agreed pilot program, selected based on factors including project readiness, strategic priority and available resources. The pilot is expected to provide a framework for applying the parties’ combined nuclear, infrastructure development and secure computing capabilities to a defined deployment opportunity. Any pilot would be subject to a separate project-specific agreement establishing its scope, timeline, commercial terms and deliverables.
In parallel, the parties expect to evaluate potential host sites and end-users, engage relevant government agencies, regulators, financiers and infrastructure partners, and assess supply-chain, manufacturing, localization and workforce requirements for potential deployments.
“Advanced nuclear is moving beyond traditional power markets as AI, national security and other strategic industries seek secure, reliable and resilient sources of energy. This collaboration is designed to position NANO Nuclear’s technology at the center of that emerging opportunity,” said James Walker, Chief Executive Officer of NANO Nuclear Energy. “Being selected as a preferred nuclear technology and services provider for opportunities explored under this collaboration is another meaningful step in expanding future commercial pathways for our company. By combining our reactor and fuel capabilities with IP3’s relationships, project integrator and capital formation capabilities and Cybernetic Intelligence’s expertise in sovereign AI, we have the opportunity to pursue projects where the need for advanced nuclear power is tied to identifiable demand.”
“The opportunity in advanced nuclear now turns on execution. We must convert strong technology into financeable, buildable projects. That requires the right technology, customers, capital, regulatory strategy and development expertise in one place,” said Michael W. Hewitt, Chief Executive Officer of IP3 Corporation. “NANO Nuclear brings deep expertise on advanced reactor technology and fuel capabilities to the table. Together we look forward to exploring projects across the infrastructure markets where energy security and resilience matter most.”
“Compute sovereignty ultimately depends on energy sovereignty. As governments and critical industries deploy increasingly powerful AI systems, access to secure, dedicated and resilient power will become an increasingly important part of the infrastructure equation,” said Maxim Serezhin, Chief Executive Officer of Cybernetic Intelligence. “We believe advanced nuclear can play an important role in meeting that requirement. By bringing together Cybernetic Intelligence’s AI capabilities and vertically integrated compute systems, IP3’s infrastructure development expertise and NANO Nuclear’s advanced nuclear platform, this collaboration creates a compelling foundation to explore sovereign AI applications.”
The LOI, which was formally executed last month, represents a non-binding and non-excusive framework for exploration of opportunities among the parties. Any future projects remain subject to further diligence, applicable regulatory and governmental approvals, financing and the negotiation and execution of applicable definitive agreements.
About IP3 Corporation
IP3 is a U.S.-based nuclear infrastructure integrator, operating through a buy-side integrator model, focused on the development and operation of peaceful and secure civilian nuclear power projects domestically and globally, with wholly owned subsidiaries IP3 Security Co. and Allied Nuclear Partners Inc. that extend IP3’s reach across security and nuclear partnership domains.
About Cybernetic Intelligence LLC
Cybernetic Intelligence develops distributed, autonomous, explainable, and auditable AI systems designed for mission critical industrial, military, and intelligence operations. Our software bridges soft computing, control theory, advanced sensing, and mission-ready engineering to enable real-time environmental response and autonomous reasoning optimization. www.cyberintel.tech
About NANO Nuclear Energy, Inc.
NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.
Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, the ZEUS™ system, a portable solid core battery reactor, and the space focused, portable LOKI MMR™system, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.
Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.
HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.
NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.
This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “future,” “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future, although forward-looking statements could be denoted by other terms as well. In this press release, forward-looking statements include those relating to the anticipated potential benefits to NANO Nuclear of the LOI with IP3 and Cybernetic Intelligence described herein (which LOI is non-binding, non-exclusive and subject to risks and uncertainties and potential opportunities to be explored under such LOI). These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to, risks associated with the preliminary, non-binding nature of the framework LOI described herein, including that definitive agreements with respect to any projects may never be entered into by the Company under the LOI, as well as the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) risks related to our ability to obtain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
